Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

MYL
Mylan N.V.
stock NASDAQ

Inactive
Nov 16, 2020
15.86USD+1.961%(+0.31)26,574,166
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplits
Historical
Historical
Price & Volume
Splits
Exchange VolumeDark Pool LevelsDark Pool Prints
Exchanges
Exchanges
Exchange Volume
Dark Pool Levels
Dark Pool Prints
Short VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)
Shorts
Shorts
Short Volume
Short Interest - Daily
Short Interest
Borrow Fee (CTB)
Failure to Deliver (FTD)
TrendsNews
News
More
Trends
News
Nov 16, 2020
08:40AM EST  Benzinga Pro's Top 5 Stocks To Watch For Monday, Nov. 16, 2020: MRNA, WMT, MYL, NVDA, IMMR   Benzinga
07:59AM EST  Pfizer Completes Combination Of Upjohn And Mylan; Viatris   RTTNews
07:37AM EST  Pfizer Reports Completion Of Transaction To Combine Its Upjohn Business With Mylan   Benzinga
07:36AM EST  Pfizer Completes Transaction To Spin Off Upjohn Business And combine It With Mylan To Form Viatris   RTTNews
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
07:04AM EST  Mylan N.V. (MYL) announced earnings for third quarter that decreased from the same period last year.   RTTNews
07:01AM EST  Mylan Q3 EPS $0.36, Adj. Net Earnings $679.7M vs $604.4M In Same Qtr. Last Year, Adj. EBITDA $1.01B vs $922.8M Year Over Year, Sales $2.97B Miss $3.00B Estimate   Benzinga
07:01AM EST  Mylan Q3 EPS $0.36 Vs $0.37 Last Year   RTTNews
07:00AM EST  Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the   PR Newswire
03:33AM EST  Earnings Scheduled For November 6, 2020   Benzinga
Nov 2, 2020
07:31AM EST  Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill   PR Newswire
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 30, 2020
01:46PM EDT  Mylan And Pfizer Receive Clearance From US Federal Trade Commission For Proposed Combination Of Mylan And Upjohn   RTTNews
01:40PM EDT  Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for   PR Newswire
01:23PM EDT  Mylan, Pfizer Receive Clearance From Federal Trade Commission For Proposed Combination Of Mylan And Upjohn   Benzinga
01:22PM EDT  Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn   Business Wire
12:32PM EDT  UPDATE: Pfizer Will Spinoff Its Upjohn Unit And Combine It With Mylan; New Entity Will Be Called Viatris; Pfizer Will Receive $12B From Viatris As Partial Consideration For Upjohn Spinoff   Benzinga
12:31PM EDT  UPDATE: Pfizer, Mylan Have Agreed To Divest Assets, Abide By Other Conditions To Settle FTC Charges Related To Combination Of Pfizer's Upjohn And Mylan   Benzinga
Oct 28, 2020
11:00AM EDT  Wells Fargo Maintains Equal-Weight on Mylan, Lowers Price Target to $16   Benzinga
Oct 26, 2020
09:51AM EDT  Mylan Option Alert: Nov 13 $13 Puts at the Bid: 4000 @ $0.141 vs 26 OI; Earnings 11/6 Before Open [est] Ref=$15.31   Benzinga
Oct 7, 2020
07:49AM EDT  A Look Into Mylan's Debt   Benzinga
07:05AM EDT  Mapi Pharma Announces Commissioning of a Vaccine Production Facility to Support the Supply of COVID-19 Vaccines to Israel and EU Countries   Benzinga
07:00AM EDT  Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company, today announced that it will dedicate capacity at its manufacturing facility to support the global effort to provide COVID-19 vaccination to Israel, the EU and globally.   GlobeNewswire Inc
Sep 15, 2020
07:59AM EDT  Mylan N.V. (MYL) said Tuesday that the company and development partner Synthon has won a significant European Patent Office ruling related to Copaxone 40 mg/mL.   RTTNews
07:24AM EDT  Mylan (MYL) and Pfizer Inc. (PFE) announced that the companies have received final approval from the European Commission or EC for the proposed combination of Mylan and Pfizer Inc.'s Upjohn business.   RTTNews
07:18AM EDT  Mylan, Synthon, Win Significant European Patent Office Ruling Related To Copaxone 40mg/mL   RTTNews
07:15AM EDT  Mylan and Development Partner, Synthon, Win Significant European Patent Office   PR Newswire
07:04AM EDT  Mylan and Pfizer Receive European Commission Approval For Proposed Combination Of Mylan And Upjohn   Benzinga
07:01AM EDT  Mylan, Pfizer Receive European Commission Approval For Proposed Combination Of Mylan And Upjohn   RTTNews
07:01AM EDT  Mylan and Pfizer Receive European Commission Approval for Proposed Combination   PR Newswire
Sep 9, 2020
01:08PM EDT  Mylan to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare   PR Newswire
01:06PM EDT  Mylan to Present at the BofA Securities Virtual Global Healthcare Conference   PR Newswire
Sep 8, 2020
06:02AM EDT  A Peek Into The Markets: US Stock Futures Mostly Lower Following Last Week's Plunge   Benzinga
04:58AM EDT  Mylan to Acquire Aspen's Thrombosis Business in Europe for 641.9M   Benzinga
02:16AM EDT  Mylan N.V. (MYL), on Tuesday, said it agreed to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Ltd.'s thrombosis business in Europe for EUR 641.9 million, subject to customary closing conditions and European regulatory clearances.   RTTNews
02:05AM EDT  Mylan To Buy Intellectual Property, Commercialization Right Of Aspen Thrombosis Business In Europe For EUR 641.9 Mln   RTTNews
02:01AM EDT  Mylan to Acquire Aspen's Thrombosis Business in Europe   PR Newswire
Sep 2, 2020
10:27AM EDT  Generic and specialty pharma company Mylan N.V. said its U.S.-based business Mylan Institutional LLC recalled four lots of Amiodarone HCl Injection, USP and Tranexamic Acid Injection, USP for potential interchanging of cartons, according to the U.S. Food and Drug Administration or FDA.   RTTNews
Sep 1, 2020
05:19PM EDT  CORRECTION: Medtronic Announces Details Of New Operating Model   Benzinga
05:17PM EDT  Medtronic 8-K Shows Co. Implementing New Operating Model Designed To Make Co. 'more nimble and competitive organization focused on accelerating innovation, enhancing the customer experience, driving revenue growth, and winning market share...'   Benzinga
12:02PM EDT  'Mylan Warned by FDA Over India Drug Plant's Quality Controls' -Bloomberg Report   Benzinga
Aug 31, 2020
01:06PM EDT  Pharmaceutical Companies Are Doing Much More Than Battling COVID-19   Benzinga
06:17AM EDT  Mylan N.V. (MYL) and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., on Monday, announced the U.S. launch of Semglee in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not recommended for the treatment of diabetic ketoacidosis, the companies noted.   RTTNews
06:02AM EDT  Mylan and Biocon Biologics Announce Launch of Semglee in the U.S. to Expand Access for Patients Living with Diabetes   Benzinga
06:02AM EDT  Mylan And Biocon Biologics Launch Semglee In The U.S.   RTTNews
06:01AM EDT  Mylan and Biocon Biologics Announce Launch of Semglee(tm) (insulin glargine   PR Newswire
Aug 28, 2020
07:44PM EDT  Mylan Initiates Voluntary Nationwide Recall Of Various Injections   RTTNews
06:31PM EDT  Injection, USP and Tranexamic Acid Injection, USP Due to Carton Label Mix-Up   PR Newswire
Aug 23, 2020
12:46PM EDT  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the Class Period), of the important August 25, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Mylan investors under the federal securities laws.   GlobeNewswire Inc
Aug 19, 2020
07:06AM EDT  Mylan Announces Launch Of FFA-Approved Therapeutically Equivalent, Substitutable Generic Of Biogen's Tecfidera Capsules   Benzinga
07:02AM EDT  Mylan Launches First FDA-approved Therapeutically Equivalent, Substitutable Generic Of Biogen's Tecfidera Capsules   RTTNews
07:01AM EDT  Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a   PR Newswire
Aug 18, 2020
03:19PM EDT  Mylan Receives FDA Approval For Generic Tecfidera   Benzinga
Aug 12, 2020
03:38PM EDT  ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Mylan N.V. Investors of Important   PR Newswire
09:19AM EDT  Mylan, Sesame Workshop Partner To Provide Socio-Emotional Support Resources To Families Impacted By Coronavirus   Benzinga
09:10AM EDT  Mylan, Sesame Workshop To Provide Socio-Emotional Support Resources To Families Impacted By COVID-19   RTTNews
09:01AM EDT  Mylan and Sesame Workshop Partner to Provide Socio-Emotional Support Resources   PR Newswire
Aug 11, 2020
10:51AM EDT  UBS Maintains Neutral on Mylan, Raises Price Target to $18   Benzinga
Aug 6, 2020
11:46AM EDT  Mylan Says Viatris' FY 2021 Guidance To Take Into Account All Relevant Country-Specific Headwinds, Including Any Effects Of A Continuing Coronavirus Pandemic   Benzinga
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
07:01AM EDT  Mylan N.V. (MYL) reported that its second quarter net earnings were $39.4 million or $0.08 per share, compared to a loss of $168.5 million or $0.33 per share in the same quarter last year.   RTTNews
06:34AM EDT  Mylan N.V. Q2 GAAP Net Income $39.4 Mln Vs. Net Loss $168.5 Mln Last Year   RTTNews
06:33AM EDT  Mylan Sees FY20 Sales $11.5B-$12.0B vs $11.62B Est.   Benzinga
06:33AM EDT  Mylan Q2 EPS $0.08 Vs Loss $0.33 Prior Year   RTTNews
06:32AM EDT  Mylan Q2 GAAP EPS $0.08 Does Not Compare To $0.98 Estimate, Sales $2.73B Miss $2.75B Estimate   Benzinga
06:31AM EDT  Mylan Reports Strong Second Quarter and First Half 2020 Results and Updates   PR Newswire
Aug 4, 2020
12:08PM EDT  Move Over Big Tech; This Week Is All About Blue Chips   Benzinga
Jul 31, 2020
10:16AM EDT  UPDATE: US Appeals Court Says Takeda Failed to Show Co. Was Likely To Succeed On Merits Or That It Would Be Irreparably Harmed Absent An Injunction   Benzinga
Jul 29, 2020
11:31AM EDT  Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential   Benzinga
Jul 28, 2020
11:55AM EDT  Monumental Earnings Week Begins on Tuesday   Benzinga
Jul 22, 2020
07:30AM EDT  Mylan to Release Second Quarter 2020 Financial Results on Aug. 6, 2020   PR Newswire
Jul 21, 2020
06:40PM EDT  August 25 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MYL   PR Newswire
Jul 18, 2020
01:45PM EDT  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the Class Period), of the important August 25, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Mylan investors under the federal securities laws.   GlobeNewswire Inc
Jul 15, 2020
05:55PM EDT  4 Ways Biogen's Tecfidera Generic Battle Could Play Out For The Stock   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC